

David M Weinstock

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6570337/david-m-weinstock-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

168
papers

8,689
citations

52
h-index

92
g-index

176
ext. papers

11,031
ext. citations

9
avg, IF

5.57
L-index

#	Paper	IF	Citations
168	Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma.. <i>Blood Cancer Discovery</i> , 2022 , 3, 154-169	7	2
167	A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia.. <i>Genes and Development</i> , 2022 ,	12.6	1
166	Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis. <i>Cancer Discovery</i> , 2021 ,	24.4	4
165	Phase II biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. <i>Blood</i> , 2021 ,	2.2	4
164	Leveraging Pathway-Interference to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021 , 138, 616-616	2.2	1
163	Identification of a Conserved Intracellular Loop (CIL) Structure That Scaffolds PIP3 to Amplify Oncogenic Signaling during Malignant B-Cell Transformation. <i>Blood</i> , 2021 , 138, 868-868	2.2	
162	Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (NCT#03269669): SWOG S1608. <i>Blood</i> , 2021 , 138, 2425-2425	2.2	
161	Maturity State and MCL-1 Dependence Predetermines Response to NOTCH1 Inhibition in T-ALL. <i>Blood</i> , 2021 , 138, 3484-3484	2.2	
160	Structural Basis of Feedback Control of Oncogenic Signaling in B-Lymphoid Malignancies. <i>Blood</i> , 2021 , 138, 355-355	2.2	
159	Low-cost transcriptional diagnostic to accurately categorize lymphomas in low- and middle-income countries. <i>Blood Advances</i> , 2021 , 5, 2447-2455	7.8	3
158	Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia. <i>iScience</i> , 2021 , 24, 102651	6.1	0
157	RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia. <i>Oncogene</i> , 2021 , 40, 746-762	9.2	4
156	Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features. <i>Blood Advances</i> , 2021 , 5, 649-661	7.8	7
155	Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway. <i>Blood</i> , 2021 , 138, 2435-2440	2.2	0
154	On Grieving for the Out-of-Practice. <i>New England Journal of Medicine</i> , 2020 , 383, 1809-1811	59.2	1
153	Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma. <i>Cell Reports</i> , 2020 , 31, 107522	10.6	24
152	Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions. <i>Blood</i> , 2020 , 135, 1467-1471	2.2	13

151	A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries. <i>Cancers</i> , 2020 , 12,	6.6	3
150	Breaking Down the Barriers to Define and Treat NK/T Cell Lymphoma. <i>Cancer Cell</i> , 2020 , 37, 263-265	24.3	0
149	TMOD-03. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. <i>Neuro-Oncology</i> , 2020 , 22, ii228-ii228	1	
148	AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells. <i>Clinical Cancer Research</i> , 2020 , 26, 922-934	12.9	80
147	46. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , 2020 , 2, ii9-ii9	0.9	78
146	Polymerase β promotes chromosomal rearrangements and imprecise double-strand break repair. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 27566-27577	11.5	4
145	Signalling input from divergent pathways subverts B cell transformation. <i>Nature</i> , 2020 , 583, 845-851	50.4	16
144	DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 95	22.4	26
143	Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2020 , 38, 872-890.e6	24.3	16
142	Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma. <i>Blood Advances</i> , 2020 , 4, 1265-1269	7.8	3
141	Next-generation characterization of the Cancer Cell Line Encyclopedia. <i>Nature</i> , 2019 , 569, 503-508	50.4	962
140	Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents. <i>Cancer Discovery</i> , 2019 , 9, 944-961	24.4	20
139	Targeted inhibition of CD47-SIRP α requires Fc-Fc γ R interactions to maximize activity in T-cell lymphomas. <i>Blood</i> , 2019 , 134, 1430-1440	2.2	21
138	Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. <i>PLoS ONE</i> , 2019 , 14, e0221288	3.7	12
137	DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. <i>Journal of Clinical Investigation</i> , 2019 , 129, 5005-5019	15.9	39
136	Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma. <i>Blood</i> , 2019 , 134, 4019-4019	2.2	11
135	A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults. <i>Blood</i> , 2019 , 134, 3879-3879	2.2	4
134	Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling. <i>Blood</i> , 2019 , 134, 393-393	2.2	

133	DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia. <i>Blood</i> , 2019 , 134, 303-303	2.2	1
132	Co-Expression of SYK and ZAP70 Subverts Negative B-Cell Selection and Enables Oncogenic Signaling in Multiple B-Cell Malignancies. <i>Blood</i> , 2019 , 134, 295-295	2.2	
131	Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia. <i>Blood</i> , 2019 , 134, 2551-2551	2.2	
130	Enhancer Rewiring Dependent Switch from BCL2 to MCL1 Dependency Predicts NOTCH1 Inhibition Response in T-ALL. <i>Blood</i> , 2019 , 134, 3948-3948	2.2	
129	A Clinically-Indolent Variant of Extranodal NK/T Cell Lymphoma with Unique Immunophenotypic Profile and Superior Outcome. <i>Blood</i> , 2019 , 134, 5278-5278	2.2	
128	TFH lymphomas: the times they aza-changinR. <i>Blood</i> , 2019 , 134, 1364-1365	2.2	0
127	Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models. <i>Scientific Reports</i> , 2019 , 9, 17161	4.9	12
126	Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. <i>Clinical Cancer Research</i> , 2019 , 25, 7046-7057	12.9	29
125	Bruton tyrosine kinase degradation as a therapeutic strategy for cancer. <i>Blood</i> , 2019 , 133, 952-961	2.2	73
124	Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. <i>Blood</i> , 2019 , 133, 566-575	2.2	25
123	An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. <i>Leukemia</i> , 2018 , 32, 1970-1983	10.7	173
122	Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications. <i>British Journal of Haematology</i> , 2018 , 181, 642-652	4.5	31
121	Targeting minimal residual disease: a path to cure?. <i>Nature Reviews Cancer</i> , 2018 , 18, 255-263	31.3	51
120	Clinicogenetic risk modeling in ATL. <i>Blood</i> , 2018 , 131, 159-160	2.2	3
119	Activity of the PI3K- γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. <i>Blood</i> , 2018 , 131, 888-898	2.2	140
118	Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type. <i>Journal of Investigative Dermatology</i> , 2018 , 138, 2365-2376	4.3	39
117	Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility. <i>PLoS ONE</i> , 2018 , 13, e0199708	3.7	2
116	Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. <i>Blood</i> , 2018 , 132, 1495-1506	2.2	69

115	Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles. <i>Blood</i> , 2018 , 132, 1695-1702	2.2	30
114	Triple Degradation of BTK, IKZF1 and IKZF3 in B-Cell Malignancies. <i>Blood</i> , 2018 , 132, 263-263	2.2	
113	Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 514-520	4.7	27
112	Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in rearranged and/or driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. <i>Oncotarget</i> , 2018 , 9, 8027-8041	3.3	28
111	Parp3 promotes long-range end joining in murine cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 10076-10081	11.5	7
110	Challenges and implications of genomics for T-cell lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2018 , 2018, 63-68	3.1	8
109	RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice. <i>Blood</i> , 2018 , 132, 935-947	2.2	57
108	Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. <i>Nature Communications</i> , 2018 , 9, 2024	17.4	54
107	Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with mutations. <i>EMBO Molecular Medicine</i> , 2017 , 9, 498-507	12	61
106	Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2017 , 23, 1012-1024	12.9	65
105	PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA. <i>Nature Communications</i> , 2017 , 8, 15110	17.4	26
104	The promise of organ and tissue preservation to transform medicine. <i>Nature Biotechnology</i> , 2017 , 35, 530-542	44.5	246
103	Functional proteogenomics reveals biomarkers and therapeutic targets in lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 6581-6586	11.5	18
102	It Takes a Village to Unmask HSTL. <i>Cancer Discovery</i> , 2017 , 7, 352-353	24.4	1
101	Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2017 , 177, 271-282	4.5	18
100	PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. <i>Cancer Research</i> , 2017 , 77, e62-e66	10.1	65
99	Inhibition of USP10 induces degradation of oncogenic FLT3. <i>Nature Chemical Biology</i> , 2017 , 13, 1207-1215	15.7	57
98	A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas. <i>Cell Reports</i> , 2017 , 21, 784-797	10.6	45

97	The promises and challenges of using gene mutations for patient stratification in follicular lymphoma. <i>Blood</i> , 2017 , 130, 1491-1498	2.2	23
96	Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. <i>Nature Genetics</i> , 2017 , 49, 10-16	36.3	167
95	Constitutive Ras signaling and inactivation cooperate during the development of B-ALL in mice. <i>Blood Advances</i> , 2017 , 1, 2361-2374	7.8	9
94	Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. <i>Oncotarget</i> , 2017 , 8, 52026-52044	3.3	17
93	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. <i>Blood</i> , 2016 , 127, 2203-13	2.2	51
92	Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. <i>Cell Reports</i> , 2016 , 14, 429-439	10.6	91
91	Buying cures versus renting health: Financing health care with consumer loans. <i>Science Translational Medicine</i> , 2016 , 8, 327ps6	17.5	17
90	mTOR Kinase Inhibitors Enhance Efficacy of TKIs in Preclinical Models of Ph-like B-ALL. <i>Blood</i> , 2016 , 128, 2763-2763	2.2	4
89	A Functional Characterization of BCL2-Family Members Identifies BH3 Mimetics As Potential Therapeutics in T-Cell Lymphomas. <i>Blood</i> , 2016 , 128, 292-292	2.2	1
88	T-Cell Lymphoma Patient-Derived Xenografts and Newly Developed Cell Lines Recapitulate Aspects of Disease Biology and Represent Novel Tools for Preclinical Drug Development. <i>Blood</i> , 2016 , 128, 3015-3015	2.2	1
87	Notch-Regulated Enhancers in B-Cell Lymphoma Activate MYC and Potentiate B-Cell Receptor Signaling. <i>Blood</i> , 2016 , 128, 457-457	2.2	1
86	Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016 , 128, 830-830	2.2	3
85	Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones. <i>Oncotarget</i> , 2016 , 7, 51494-51502	3.3	27
84	Examination of Phosphoprotein Targets in Timed Samples from Patients with RAS-Mutated AML during Concurrent Treatment with Alpelisib and Binimetinib on the Phase Ib Clinical Trial CMEK162X2109. <i>Blood</i> , 2016 , 128, 2749-2749	2.2	
83	FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016 , 128, 1681-1681	2.2	
82	Exploring RhoA G17V-Mediated T-Cell Dysfunction. <i>Blood</i> , 2016 , 128, 1567-1567	2.2	
81	Inhibition of USP10 Induces Degradation of Oncogenic FLT3: A Novel Approach to Therapy of Leukemia. <i>Blood</i> , 2016 , 128, 524-524	2.2	
80	Anti-Leukemic Activity of the TYK2 Selective Inhibitor Ndi-031301 in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016 , 128, 1596-1596	2.2	

79	HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma. <i>Blood</i> , 2016 , 128, 2517-2526	2.2	30
78	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016 , 29, 574-586	24.3	154
77	Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. <i>Blood</i> , 2016 , 128, 1093-100	2.2	78
76	Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. <i>Blood</i> , 2016 , 128, 1112-20	2.2	119
75	High-throughput measurement of single-cell growth rates using serial microfluidic mass sensor arrays. <i>Nature Biotechnology</i> , 2016 , 34, 1052-1059	44.5	152
74	Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. <i>Nature Biotechnology</i> , 2016 , 34, 1161-1167	44.5	68
73	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. <i>Lancet Oncology</i> , 2015 , 16, 1111-1122	21.7	347
72	Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015 , 28, 29-41	24.3	75
71	Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia. <i>Science Advances</i> , 2015 , 1, e1500221	14.3	52
70	Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. <i>Nature Medicine</i> , 2015 , 21, 71-5	50.5	60
69	A roadmap for discovery and translation in lymphoma. <i>Blood</i> , 2015 , 125, 2175-7	2.2	16
68	Combined Targeting of JAK2 with a Type II JAK2 Inhibitor and mTOR with a TOR Kinase Inhibitor Constitutes Synthetic Activity in JAK2-Driven Ph-like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 2529-2529	2.2	3
67	Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma. <i>Blood</i> , 2015 , 126, 3252-3252	2.2	1
66	A Clinicogenetic Risk Model (m7-FLIPI) Prospectively Identifies One-Half of Patients with Early Disease Progression of Follicular Lymphoma after First-Line Immunochemotherapy. <i>Blood</i> , 2015 , 126, 333-333	2.2	6
65	Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2015 , 126, 522-522	2.2	3
64	Disruptive ARID1A Mutations in Follicular Lymphoma Impair DNA Repair Efficiency and Are Associated with Favorable Outcome in Patients Receiving First-Line Immunochemotherapy. <i>Blood</i> , 2015 , 126, 571-571	2.2	1
63	The MDM2 Inhibitor NVP-CGM097 Is Highly Active in a Randomized Preclinical Trial of B-Cell Acute Lymphoblastic Leukemia Patient Derived Xenografts. <i>Blood</i> , 2015 , 126, 797-797	2.2	6
62	Phenotypic and Transcriptional Characterization of Non-Hodgkin Lymphomas from Malawi Defines Targetable Disease Subsets. <i>Blood</i> , 2015 , 126, 2655-2655	2.2	

61	B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development. <i>Blood</i> , 2015 , 126, 4001-4001	2.2	
60	Diffuse Large B-Cell Lymphoma Patient-Derived Xenograft Models Capture Molecular and Biologic Heterogeneity and Inform Therapy. <i>Blood</i> , 2015 , 126, 817-817	2.2	
59	Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. <i>Nature Genetics</i> , 2014 , 46, 618-23	36.3	84
58	A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2014 , 123, 1293-6	2.2	255
57	Ubiquitin-specific peptidase 20 regulates Rad17 stability, checkpoint kinase 1 phosphorylation and DNA repair by homologous recombination. <i>Journal of Biological Chemistry</i> , 2014 , 289, 22739-22748	5.4	22
56	PARP1 is required for chromosomal translocations. <i>Blood</i> , 2013 , 121, 4359-65	2.2	56
55	Inactivation of Uaf1 causes defective homologous recombination and early embryonic lethality in mice. <i>Molecular and Cellular Biology</i> , 2013 , 33, 4360-70	4.8	33
54	Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. <i>PLoS ONE</i> , 2013 , 8, e67306	3.7	79
53	Efficacy and Mechanisms Of The mTOR Inhibitor AZD2014 Combined With L-Asparaginase Or JAK2 Inhibitor TG101348 In ALL. <i>Blood</i> , 2013 , 122, 1282-1282	2.2	2
52	Loss-Of-Function Mutations In The Splicing Factor ZRSR2 Are Common In Blastic Plasmacytoid Dendritic Cell Neoplasm and Have Male Predominance. <i>Blood</i> , 2013 , 122, 741-741	2.2	15
51	HSP90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase. <i>Blood</i> , 2013 , 122, 2528-2528	2.2	
50	Integrated Analysis Of CRLF2 Signaling In Acute Lymphoblastic Leukemia Identifies Polo-Like Kinase 1 As a Therapeutic Target. <i>Blood</i> , 2013 , 122, 2667-2667	2.2	
49	JAK2 L884P Mutation Confers Resistance To The Type II JAK2 Inhibitor NVP-BBT594 When Co-Occurring With JAK2 R683G But Not JAK2 V617F. <i>Blood</i> , 2013 , 122, 1429-1429	2.2	
48	Targeting Oncogenic Interleukin-7 Receptor Signaling With N-Acetylcysteine In T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013 , 122, 2535-2535	2.2	
47	The Beta-Subunit Of Heterotrimeric G Proteins Harbors Gain-Of-Function Mutations In Multiple Hematologic Malignancies. <i>Blood</i> , 2013 , 122, 2510-2510	2.2	
46	BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. <i>Blood</i> , 2012 , 120, 2843-52	2.2	298
45	BCL2 suppresses PARP1 function and nonapoptotic cell death. <i>Cancer Research</i> , 2012 , 72, 4193-203	10.1	37
44	Next-generation cDNA screening for oncogene and resistance phenotypes. <i>PLoS ONE</i> , 2012 , 7, e49201	3.7	8

43	Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. <i>Cancer Discovery</i> , 2012 , 2, 47-55	24.4	69
42	Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. <i>Journal of Experimental Medicine</i> , 2012 , 209, 259-73	16.6	129
41	Medical planning and response for a nuclear detonation: a practical guide. <i>Biosecurity and Bioterrorism</i> , 2012 , 10, 346-71		22
40	Planning and response to radiation exposures. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1262-3	4.7	1
39	miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. <i>Molecular Cell</i> , 2011 , 41, 210-20	17.6	355
38	Repair at single targeted DNA double-strand breaks in pluripotent and differentiated human cells. <i>PLoS ONE</i> , 2011 , 6, e20514	3.7	35
37	Radiation injury after a nuclear detonation: medical consequences and the need for scarce resources allocation. <i>Disaster Medicine and Public Health Preparedness</i> , 2011 , 5 Suppl 1, S32-44	2.8	146
36	Allocation of scarce resources after a nuclear detonation: setting the context. <i>Disaster Medicine and Public Health Preparedness</i> , 2011 , 5 Suppl 1, S20-31	2.8	55
35	First global consensus for evidence-based management of the hematopoietic syndrome resulting from exposure to ionizing radiation. <i>Disaster Medicine and Public Health Preparedness</i> , 2011 , 5, 202-12	2.8	67
34	Literature review and global consensus on management of acute radiation syndrome affecting nonhematopoietic organ systems. <i>Disaster Medicine and Public Health Preparedness</i> , 2011 , 5, 183-201	2.8	54
33	Radiation injury treatment network (RITN): healthcare professionals preparing for a mass casualty radiological or nuclear incident. <i>International Journal of Radiation Biology</i> , 2011 , 87, 748-53	2.9	10
32	Molecular Ontogeny of Donor-Derived Lymphomas Occurring After Transplantation. <i>Blood</i> , 2011 , 118, 3671-3671	2.2	
31	Genetic Resistance to JAK2 Enzymatic Inhibitors Is Overcome by HSP90 Inhibition. <i>Blood</i> , 2011 , 118, 62-62		22
30	HSP90 Inhibition Targets JAK2 and Is Highly Effective in CRLF2-Rearranged Acute Lymphoblastic Leukemia. <i>Blood</i> , 2011 , 118, 576-576	2.2	
29	Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 252-7	11.5	268
28	The p400 ATPase regulates nucleosome stability and chromatin ubiquitination during DNA repair. <i>Journal of Cell Biology</i> , 2010 , 191, 31-43	7.3	142
27	Epstein-Barr virus, lymphoma risk and the potential role of HIV infection in IBD patients undergoing immunosuppression. <i>Digestive Diseases</i> , 2010 , 28, 519-24	3.2	8
26	Assessing surge capacity for radiation victims with marrow toxicity. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1436-41	4.7	7

25	Medical management of radiation victims in the United States. <i>Health Physics</i> , 2010 , 98, 833-7	2.3	5
24	Chromosomal translocations induced at specified loci in human stem cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 10620-5	11.5	166
23	Stem cells, multiorgan failure in radiation emergency medical preparedness: a U.S./European Consultation Workshop. <i>Stem Cells</i> , 2009 , 27, 1205-11	5.8	38
22	Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. <i>Developmental Cell</i> , 2009 , 16, 314-20	10.2	180
21	The evolution of influenza resistance and treatment. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 301, 1066-9	27.4	73
20	A PP4-phosphatase complex dephosphorylates gamma-H2AX generated during DNA replication. <i>Molecular Cell</i> , 2008 , 31, 33-46	17.6	189
19	Induction of chromosomal translocations in mouse and human cells using site-specific endonucleases. <i>Journal of the National Cancer Institute Monographs</i> , 2008 , 20-4	4.8	18
18	Radiologic and nuclear events: contingency planning for hematologists/oncologists. <i>Blood</i> , 2008 , 111, 5440-5	2.2	53
17	Response: Radiologic and nuclear events. <i>Blood</i> , 2008 , 111, 5758-5759	2.2	5
16	Formation of NHEJ-derived reciprocal chromosomal translocations does not require Ku70. <i>Nature Cell Biology</i> , 2007 , 9, 978-81	23.4	119
15	Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 615-21	4.7	162
14	BCR-ABL Induces Error-Prone Single Strand Annealing in Transformed Cells.. <i>Blood</i> , 2007 , 110, 2937-2937.2	2.2	2
13	Progression of <i>Pneumocystis jiroveci</i> pneumonia in patients receiving echinocandin therapy. <i>Clinical Infectious Diseases</i> , 2006 , 43, e92-4	11.6	44
12	Alternative pathways for the repair of RAG-induced DNA breaks. <i>Molecular and Cellular Biology</i> , 2006 , 26, 131-9	4.8	46
11	Assaying double-strand break repair pathway choice in mammalian cells using a targeted endonuclease or the RAG recombinase. <i>Methods in Enzymology</i> , 2006 , 409, 524-40	1.7	121
10	Modeling oncogenic translocations: distinct roles for double-strand break repair pathways in translocation formation in mammalian cells. <i>DNA Repair</i> , 2006 , 5, 1065-74	4.3	134
9	A model of oncogenic rearrangements: differences between chromosomal translocation mechanisms and simple double-strand break repair. <i>Blood</i> , 2006 , 107, 777-80	2.2	83
8	Adamantane resistance in influenza A. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 934-6	27.4	16

7	PCR Screening for Epstein-Barr Virus-Related Lymphoproliferative Disease (EBV-LPD) among Allogeneic Stem Cell Transplant (AlloSCT) Recipients: The Importance of T Cell Depletion.. <i>Blood</i> , 2005 , 106, 3234-3234	2.2	1
6	Postexposure prophylaxis against varicella-zoster virus infection among recipients of hematopoietic stem cell transplant: unresolved issues. <i>Infection Control and Hospital Epidemiology</i> , 2004 , 25, 603-8	2	37
5	Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. <i>New England Journal of Medicine</i> , 2003 , 348, 867-8	59.2	164
4	Rhodococcus equi: an emerging pathogen. <i>Clinical Infectious Diseases</i> , 2002 , 34, 1379-85	11.6	197
3	Rotavirus outbreak on a pediatric oncology floor: possible association with toys. <i>American Journal of Infection Control</i> , 2000 , 28, 378-80	3.8	46
2	Control of influenza A on a bone marrow transplant unit. <i>Infection Control and Hospital Epidemiology</i> , 2000 , 21, 730-2	2	81
1	Micro-region transcriptomics of fixed human tissue using Pick-Seq		2